TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36305511

Group type: EXPERIMENTAL
Intervention: Scheduled acetaminophen, gabapentin, ketorolac, and as-needed opioids (Experimental group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Scheduled acetaminophen and as-needed opioids (Control group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Scheduled acetaminophen, gabapentin, ketorolac, a regional nerve block at the free tissue donor site, scheduled acetaminophen and as-needed opioids (Experimental group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Scheduled acetaminophen and as-needed opioids (Arm A)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Scheduled gabapentin, ketorolac, a regional nerve block at the free tissue donor site, scheduled acetaminophen and as-needed opioids (Arm B)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 31
Study: 35034635

Group type: EXPERIMENTAL
Intervention: Information nudges
Number of subjects: 11775

Group type: EXPERIMENTAL
Intervention: Position nudges
Number of subjects: 11775

Group type: EXPERIMENTAL
Intervention: Combined nudges
Number of subjects: 11775

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 11775
Study: 32777606

Group type: EXPERIMENTAL
Intervention: Naltrexone/Buprenorphine (NTX/BUP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-Naltrexone/Buprenorphine (PBO-N/BUP)
Number of subjects: 0
Study: 34998804

Group type: EXPERIMENTAL
Intervention: TD‐CBT+TAU
Number of subjects: 1061

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 1061
Study: 34538072

Group type: EXPERIMENTAL
Intervention: Adavosertib (250 mg or 300 mg) taken orally once on days 1-5 and days 8-12 of a 3-week cycle
Number of subjects: 69

Group type: COMPARATOR
Intervention: Active Monitoring (AM)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Adavosertib (250 mg or 300 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Adavosertib
Number of subjects: 69
Study: 35439303

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg daily for an intended duration of 3 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 100
Study: 32188447

Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO) combined with curved incision on the anterior area of ankle
Number of subjects: 17
Study: 34669009

Group type: EXPERIMENTAL
Intervention: + DSS (Decision Support System)
Number of subjects: 194

Group type: COMPARATOR
Intervention: - DSS (no Decision Support System)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Standalone DSS (without clinician's final decision)
Number of subjects: 194
Study: 33234138

Group type: EXPERIMENTAL
Intervention: Estradiol therapy for women > 50 years
Number of subjects: 37086

Group type: COMPARATOR
Intervention: No estradiol therapy for women > 50 years
Number of subjects: 37086

Group type: EXPERIMENTAL
Intervention: Estradiol therapy for women 15–49 years
Number of subjects: 37086

Group type: COMPARATOR
Intervention: No estradiol therapy for women 15–49 years
Number of subjects: 37086
Study: 35081360

Group type: EXPERIMENTAL
Intervention: Best Practice Advisory (BPA) added to Atrial Fibrillation Decision Support Tool (AFDST)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care with AFDST available
Number of subjects: 800
Study: 34886081

Group type: EXPERIMENTAL
Intervention: Intense Endurance Training (IET)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moderate Endurance Training (MET)
Number of subjects: 16
Study: 32718319

Group type: EXPERIMENTAL
Intervention: Centralized invitations sent from a central authority involving the attending physician
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Providing attending physicians with lists of unscreened women among their patients
Number of subjects: 123

Group type: COMPARATOR
Intervention: Targeting women over 50 years old
Number of subjects: 123

Group type: COMPARATOR
Intervention: Targeting women living in deprived areas
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Allowing nurses to perform Pap smears
Number of subjects: 123

Group type: COMPARATOR
Intervention: Self-collected oncogenic papillomavirus testing
Number of subjects: 123
Study: 35270403

Group type: EXPERIMENTAL
Intervention: Internet-based multi-approach treatment (MindBlooming) consisting of psychoeducational videos and exercises over 7 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-based multi-approach treatment (MindBlooming)
Number of subjects: 0
Study: 33645253

Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp protocol with glucose targets of 200 mg/dL and >450 mg/dL, utilizing a centralized spreadsheet-based algorithm for dextrose infusion rates.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment during hyperglycemic clamps.
Number of subjects: 0
Study: 32666333

Group type: EXPERIMENTAL
Intervention: Bevacizumab every 6 weeks
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Bevacizumab every 8 weeks
Number of subjects: 191

Group type: COMPARATOR
Intervention: Bevacizumab every 4 weeks
Number of subjects: 191
Study: 35132025

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral pectointercostal fascial plane block with 20 ml of 0.25% bupivacaine plus epinephrine (5 mcg/mL)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral pectointercostal fascial plane block
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (dry needling)
Number of subjects: 70
Study: 34238659

Group type: EXPERIMENTAL
Intervention: Three‐component lifestyle intervention with short message service (SMS+)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Three‐component lifestyle intervention without SMS (SMS–)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Weight loss (general effect)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Comparison of SMS– group to CAU
Number of subjects: 183
Study: 35101109

Group type: EXPERIMENTAL
Intervention: Whole systems strengthening package including community men's and women's groups, Partnership Defined Quality Scorecard, healthcare worker training, mentorship, and provision of basic essential equipment and commodities.
Number of subjects: 4480

Group type: EXPERIMENTAL
Intervention: Whole systems strengthening package
Number of subjects: 4480
Study: 34992552

Group type: EXPERIMENTAL
Intervention: E-PAtS and usual practice
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 74
Study: 36051506

Group type: EXPERIMENTAL
Intervention: Quadriceps isometric exercises in knee extension (n=14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Quadriceps isometric exercises in knee flexion (n=15)
Number of subjects: 30
Study: 33026490

Group type: EXPERIMENTAL
Intervention: Yoga therapy (8 weekly sessions of 60 min each)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Waitlist control group (CG)
Number of subjects: 173
Study: 36417955

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (transfusion of RBCs sufficient to raise hemoglobin to at least 10 g/dL)
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (transfusion of RBCs if hemoglobin falls below 8 g/dL or for persistent angina despite medical therapy)
Number of subjects: 3500
Study: 33608319

Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen
Number of subjects: 0
Study: 32630188

Group type: EXPERIMENTAL
Intervention: Ai Chi aquatic therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined therapy (alternating dry-land therapy and Ai Chi aquatic therapy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dry-land therapy (control group)
Number of subjects: 40
Study: 35661111

Group type: EXPERIMENTAL
Intervention: Selective food response inhibition training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham training following binge memory reactivation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Training without binge memory reactivation
Number of subjects: 90
Study: 33845449

Group type: EXPERIMENTAL
Intervention: Day case tonsillectomy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Inpatient tonsillectomy
Number of subjects: 300
Study: 33043883

Group type: EXPERIMENTAL
Intervention: DMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study: 36244877

Group type: EXPERIMENTAL
Intervention: Food stress (not having enough money for food, not having enough time for cooking or shopping)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Food stress (inadequate food access, being on a special diet)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Food stress (not having enough money for food, being on a special diet)
Number of subjects: 192
Study: 35304705

Group type: EXPERIMENTAL
Intervention: Antrum Resection (AR)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Antrum Preservation (AP)
Number of subjects: 109
Study: 33023894

Group type: EXPERIMENTAL
Intervention: Combination treatment with sodium nitrite (40 mg twice daily) and isoquercetin (225 mg once daily) for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination treatment with sodium nitrite and isoquercetin
Number of subjects: 70
Study: 32998993

Group type: EXPERIMENTAL
Intervention: Blinding of outcome assessors
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Blinding of participants
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Blinding of data managers
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Blinding of statisticians
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Rejection of the null hypothesis on the primary outcome(s)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Discussion of potential bias risk from lack of blinding
Number of subjects: 63
Study: 33109661

Group type: EXPERIMENTAL
Intervention: Nebuliser with data recording and transfer capability, linked to a software platform, and strategies to support adherence to nebulised treatments facilitated by interventionists over 5 months (+/‐ 1 month)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Interventionists conducting review visits
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Process evaluation of adherence support intervention
Number of subjects: 14
Study: 35131974

Group type: EXPERIMENTAL
Intervention: Heparinized saline (10-100 U/mL; CVAD-type dependent)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 61
Study: 34898455

Group type: EXPERIMENTAL
Intervention: Video consultations
Number of subjects: 233

Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 233
Study: 32955293

Group type: EXPERIMENTAL
Intervention: Awe walk intervention (15-min outdoor walks for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control walk group (15-min outdoor walks for 8 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Awe walk intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control walk group
Number of subjects: 60
Study: 34310411

Group type: EXPERIMENTAL
Intervention: Screening Clinical Breast Examination (CBE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modern screening mammography
Number of subjects: 0
Study: 32487250

Group type: EXPERIMENTAL
Intervention: PST-IPV (Problem Solving Therapy tailored for IPV)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard PST (Problem Solving Therapy)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Enhanced usual care (information about sources of support)
Number of subjects: 75
Study: 34009787

Group type: EXPERIMENTAL
Intervention: Typical race position (RP)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Modified upright position (UP)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Traditional measures of vascular responsiveness
Number of subjects: 1
Study: 33606090

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body mass)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 20
Study: 32731812

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐Up (ABC) intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ABC intervention
Number of subjects: 68
Study: 34716213

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg daily for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35141484

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) - 25 patients, 3 sessions (once per week, 1.8 bar pneumatic pressure, 10 Hz frequency, 2,000 pulses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Supervised exercises with neuromuscular inhibition (NMI) technique - 25 patients, 3 times per week for three weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison between rESWT and NMI exercises
Number of subjects: 50
Study: 35428697

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg monthly for ≤6 years
Number of subjects: 424
Study: 33040356

Group type: EXPERIMENTAL
Intervention: Less-severe COL4A5 variant group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Severe COL4A5 variant group
Number of subjects: 60
Study: 35230415

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35307033

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus rosuvastatin 5 mg daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rosuvastatin 5 mg daily
Number of subjects: 70
Study: 33837117

Group type: EXPERIMENTAL
Intervention: Brain MRI with average apparent diffusion coefficient (ADC) value and percentage of brain voxels with ADC <650 × 10‐6 mm2/s and <450 × 10‐6 mm2/s
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Multivariable model including clinical characteristics, EEG, somatosensory evoked potentials (SSEP), and ADC value
Number of subjects: 79
Study: 35285882

Group type: EXPERIMENTAL
Intervention: Soft ultra-processed meal
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Soft minimally processed meal
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hard minimally processed meal
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hard ultra-processed meal
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Total energy intake across the day
Number of subjects: 50
Study: 34912072

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Continuous energy restriction (CER)
Number of subjects: 172
Study: 33714585

Group type: EXPERIMENTAL
Intervention: Beverage containing Lactobacillus paracasei LC-37
Number of subjects: 0
Study: 32782010

Group type: EXPERIMENTAL
Intervention: 5 g/day thylakoid
Number of subjects: 48
Study: 34653352

Group type: EXPERIMENTAL
Intervention: Belin ABCD Progression Display (BAPD)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional metrics (minimum corneal thickness)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional metrics (central corneal thickness)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional metrics (maximum keratometry)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional metrics (corneal astigmatism)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional metrics (back mean keratometry)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Conventional metrics (front mean keratometry)
Number of subjects: 155
Study: 32986105

Group type: EXPERIMENTAL
Intervention: Targeted gene testing (TGT) and tailored first-line therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empirical imatinib therapy
Number of subjects: 0
Study: 35058270

Group type: EXPERIMENTAL
Intervention: UPSIDES Proportionate Translation Methodology (SIS)
Number of subjects: 108
Study: 32877521

Group type: EXPERIMENTAL
Intervention: Self-taken samples from the rectum or pharynx
Number of subjects: 1793

Group type: COMPARATOR
Intervention: Clinician-taken samples from the rectum or pharynx
Number of subjects: 1793
Study: 35550194

Group type: EXPERIMENTAL
Intervention: Delivery balls plus warm showers (Group A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Delivery balls (Group B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 105
Study: 33150170

Group type: EXPERIMENTAL
Intervention: Moisturizer containing licochalcone A, 1,2‐decanediol, L‐carnitine, and salicylic acid applied twice a day for 12 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Vehicle moisturizer applied twice a day for 12 weeks
Number of subjects: 110
Study: 36423733

Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) and CTO-PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal Medical Therapy (OMT) alone
Number of subjects: 0
Study: 35776028

Group type: EXPERIMENTAL
Intervention: Midazolam-based total intravenous anesthesia (TIVA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sevoflurane-based inhalation anesthesia (SEVO)
Number of subjects: 104
Study: 33724085

Group type: EXPERIMENTAL
Intervention: Aerobic, bodyweight supported, treadmill-based training (n = 105)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Relaxation sessions (n = 95, control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 200
Study: 34006498

Group type: EXPERIMENTAL
Intervention: Pazopanib plus Pembrolizumab (Cohort A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pazopanib plus Pembrolizumab (Cohort B)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pazopanib plus Pembrolizumab (Cohort C)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy (Cohort C)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pazopanib monotherapy (Cohort C)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pazopanib plus Pembrolizumab (Cohorts A and B)
Number of subjects: 42
Study: 32703246

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 900 mg daily for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 0
Study: 34117753

Group type: EXPERIMENTAL
Intervention: Modern antiretroviral therapy (ART) regimens, specifically integrase inhibitor-based ART, with a median time to viral rebound of 22 days after treatment interruption.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Early-treated participants (ART initiated during early HIV infection)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chronic-treated participants (ART initiated during chronic HIV infection)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Older protease inhibitor-based regimens (historic studies)
Number of subjects: 45
Study: 33212138

Group type: EXPERIMENTAL
Intervention: Water consumption to the dictates of thirst (sated)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Salt water mouth rinses (thirst)
Number of subjects: 15
Study: 32737097

Group type: EXPERIMENTAL
Intervention: Ensemble programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support as usual (Control)
Number of subjects: 0
Study: 32116340

Group type: EXPERIMENTAL
Intervention: Infectious dermatoses, infestations, and papular urticaria (IDIP) observed in 505 (34.9%) persons; among them, 269 (53.3%) were males and 236 (46.7%) were females (X2=34.87, p=<0.001).
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Fungal dermatoses constituted more than 90% of the diseases, primarily due to pityriasis versicolor (430 cases, 79.6%).
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Control of pityriasis versicolor will significantly affect the prevalence of infectious dermatoses.
Number of subjects: 1447
Study: 32790927

Group type: EXPERIMENTAL
Intervention: Bipolar disorder youths
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 20
Study: 33100044

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 158

Group type: COMPARATOR
Intervention: High-risk group (observational study)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Reactive hyperemia index
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Pulse wave velocity
Number of subjects: 158
Study: 35236276

Group type: EXPERIMENTAL
Intervention: SEP-227900 (80 mg)
Number of subjects: 9
Study: 32097541

Group type: EXPERIMENTAL
Intervention: Hypobaria hypoxia (HH) at altitude levels of 3,000 m and 5,500 m
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypobaria normoxia (HN)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hypobaria conditions (HN and HH)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypobaria hypoxia (HH)
Number of subjects: 9
Study: 34606378

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg plus rituximab
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo plus rituximab
Number of subjects: 150
Study: 33411187

Group type: EXPERIMENTAL
Intervention: Improved Mouth Breathing (IMB), N = 195
Number of subjects: 273

Group type: COMPARATOR
Intervention: Persistent Mouth Breathing (PMB), N = 78
Number of subjects: 273
Study: 35959845

Group type: EXPERIMENTAL
Intervention: SM DNA (530 mg day‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SM DNA (530 mg day‐1) in males
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (dextrin) in males
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SM DNA (530 mg day‐1) in females
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (dextrin) in females
Number of subjects: 50
Study: 33905171

Group type: EXPERIMENTAL
Intervention: In-person educational programme
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Social media educational programme
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 180
Study: 35395776

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 1 μg/kg and maintenance dose of 0.5 μg/kg/h)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 160
Study: 33040557

Group type: EXPERIMENTAL
Intervention: Probiotics Clostridium butyricum
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61